(Q56898533)

English

A methodological framework to enhance the clinical success of cancer immunotherapy

No description defined

In more languages

default values for all languages

No label defined

No description defined

edit

Statements

instance of

scholarly article

0 references

title

A methodological framework to enhance the clinical success of cancer immunotherapy (English)

0 references

1 reference

3

Christoph Huber

0 references

author name string

Axel Hoos

series ordinal

1

0 references

Cedrik M Britten

series ordinal

2

0 references

Jill O'Donnell-Tormey

series ordinal

4

0 references

language of work or name

English

0 references

publication date

13 October 2011

0 references

published in

Nature Biotechnology

0 references

volume

29

0 references

issue

10

0 references

page(s)

867-70

0 references

cites work

Immune parameters affecting the efficacy of chemotherapeutic regimens

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A clinical development paradigm for cancer vaccines and related biologics

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved Endpoints for Cancer Immunotherapy Trials

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cancer vaccine roller coaster

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

"MIATA"-minimal information about T cell assays

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/21997622

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NBT.2000

0 references

PubMed publication ID

21997622

0 references

(Q56898533)

A methodological framework to enhance the clinical success of cancer immunotherapy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)